Detailed Narrative
Q3 FY26 Performance Overview
Oriental Aromatics reported Q3 FY26 operating revenue of ₹252.03 crores, marking a 13% year-on-year growth, with sales volumes increasing by 10% YoY. However, the quarter saw a net loss of ₹1.92 crore and an EBITDA margin of 5.26%, down from ₹23 crore in the prior year, primarily due to pricing pressure in the ingredients market and the ongoing stabilization of the Mahad facility. The nine-month period also reflected a net loss of ₹0.67 crore on ₹748 crore revenue, with an EBITDA margin of 6.49%.
Mahad Facility Ramp-up and Challenges
The Mahad greenfield facility, a key strategic asset, commenced real production in June 2025 and is currently operating at 30-35% capacity. Management indicated it would take 'a few quarters to reach optimal utilization' and acknowledged it is a 'near-term drag on consolidated profitability.' They expect the facility to achieve 'some level of independence' in the next two quarters, with a long-term target of 30% local and 70% export for its 250-tonne capacity.
Market Dynamics and Pricing Pressure
The company continues to face a soft pricing environment in aroma ingredients, described as a 'buyer's market,' which contributed to the EBITDA moderation in Q3. While aroma chemical prices are noted to be even lower than 2018 levels, management believes they have internally 'bottomed out.' The Q3 demand mix was also less favorable than Q2 due to seasonal cooling off in categories like camphor.
North American Market and Tariff Impact
Sales to North America constitute 16-20% of the company's total sales. Historically, tariff uncertainties led American customers to buy hand-to-mouth. However, management anticipates a positive impact from recent trade deals, potentially adding 6-9% more sales, as clarity on landed costs and a more stable duty structure (India retaining a 20% advantage over China) encourages renewed buying and stock building.
Strategic Focus and Outlook
Oriental Aromatics is prioritizing volume growth, market share expansion across camphor, fragrances, and specialty aroma ingredients, alongside internal cost and process improvements. The fragrance division shows strong performance, benefiting from softer raw material pricing and new customer wins. The company aims for 8-10% sales growth for FY26 and is confident in its business model, focusing on long-term sustainability and capitalizing on emerging opportunities.
Camphor Business and Imports
The camphor business, including the FMCG segment, faces profitability pressure. Management acknowledged the issue of camphor imports, particularly from China, which affects margins. They noted that natural camphor prices from China have started increasing, aligning with Indian camphor, and the company is focusing on process improvements to enhance profitability. Oriental Aromatics is highlighted as the world's only US FDA, WHO, and GMP certified camphor manufacturer, playing a significant role in the medical pain management space.